Filing Date |
T Date |
Ticker |
Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
#f |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2/20/25 17:14 | 2/18/25 | NMRA | Health | BioPrd | Biological Products, (No Diag | Berns Paul L | MA | DO | See Rema | 1 | S | -23 | 1.69 | 0 | -14 | 0 | 7,804 | D | ||||||||||||||
2/20/25 17:14 | 2/18/25 | NMRA | Health | BioPrd | Biological Products, (No Diag | Milligan Michael Lee | MA | O | See Rema | 1 | S | -3 | 1.69 | 0 | -2 | 22 | D | |||||||||||||||
2/20/25 17:13 | 2/18/25 | NMRA | Health | BioPrd | Biological Products, (No Diag | Aurora Daljit Singh | MA | O | Chief St | 1 | S | -14 | 1.68 | 0 | -9 | 204 | D | |||||||||||||||
2/20/25 17:12 | 2/18/25 | NMRA | Health | BioPrd | Biological Products, (No Diag | Lenz Robert A. | MA | O | Head of | 4 | S.m | -1,087 | 11.58 | 0 | -94 | 370 | D | |||||||||||||||
2/20/25 17:11 | 2/18/25 | NMRA | Health | BioPrd | Biological Products, (No Diag | Pinto Joshua | MA | O | P | 3 | S.m | -1,176 | 10.89 | 0 | -108 | 240 | D | |||||||||||||||
10/18/24 18:25 | 10/17/24 | NMRA | Health | BioPrd | Biological Products, (No Diag | Fust Matthew K | MA | D | 1 | S.dm | -371 | 17.03 | 0 | -22 | 20 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |